HIGHLIGHTS
- who: Tiffany M. Styles from the Public Health Agency of Canada University of Nebraska-Lincoln have published the paper: V2 hotspot optimized MVA vaccine expressing stabilized HIV-1 Clade C envelope Gp140 delays acquisition of heterologous Clade C Tier 2 challenges in Mamu-A*01 negative Rhesus Macaques, in the Journal: (JOURNAL)
- how: To test the immunogenicity and efficacy of the new and V2 HS optimized clade C SHIV immunogens the authors conducted the M23 macaque study. These data indicated that the majority of envelope expressed on the cell surface was present in the trimeric . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.